Agents in early development for treatment of bladder dysfunction – promise of drugs acting at TRP channels?

References

• Gormley EA, Lightner DJ, Faraday M, et al. American urological association; society of urodynamics, female pelvic medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015 May;193(5):1572–1580.
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence, 6th International Consultation on Incontinence. UK: ICUD-EAU; 2017. p. 805–956.
   Google Scholar
• Peyronnet B, Brucker BM, Michel MC. Lower urinary tract symptoms: what’s new in medical treatment? Eur Urol Focus. 2018 Jan; 4(1):17–24.
   PubMedGoogle Scholar
• Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019 Apr 30. DOI:10.1097/JU.0000000000000309.
   PubMedGoogle Scholar
• Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. pii: S0302-2838(19)30186-1 Mar 25 2019. DOI:10.1016/j.eururo.2019.02.038.
   Web of Science ®Google Scholar
• Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms. 2019 Mar 22. DOI:10.1111/luts.12262.
   Web of Science ®Google Scholar
• Andersson KE. Potential future pharmacological treatment of bladder dysfunction. Basic Clin Pharmacol Toxicol. 2016 Oct;119(Suppl 3):75–85. .
   PubMedGoogle Scholar
• Abrams P, Cardozo L, Fall M, et al. Standardisation sub-committee of the international continence society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Uren AD, Drake MJ. Definition and symptoms of underactive bladder. Investig Clin Urol. 2017 Dec;58(Suppl 2):S61–S67.
   PubMedGoogle Scholar
• Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA. 1987 Jun 12;257(22):3076–3081.
   PubMed Web of Science ®Google Scholar
• Griffiths DJ, McCracken PN, Harrison GM, et al. Urge incontinence and impaired detrusor contractility in the elderly. Neurourol Urodyn. 2002;21(2):126–131.
   PubMed Web of Science ®Google Scholar
• Chancellor MB. The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014 Sep;46(Suppl 1):S23–7.
   PubMedGoogle Scholar
• Pape J, Falconi G, De Mattos Lourenco TR, et al. Variations in bladder pain syndrome/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines. Int Urogynecol J. 2019 May 9. DOI:10.1007/s00192-019-03970-5.
   PubMed Web of Science ®Google Scholar
• Everaerts W, Gevaert T, Nilius B, et al. On the origin of bladder sensing: Tr(i)ps in urology. Neurourol Urodyn. 2008;27(4):264–273.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010 Oct;106(8):1114–1127.
   PubMed Web of Science ®Google Scholar
• Skryma R, Prevarskaya N, Gkika D, et al. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nat Rev Urol. 2011 Oct 4;8(11):617–630.
   PubMed Web of Science ®Google Scholar
• Avelino A, Charrua A, Frias B, et al. Transient receptor potential channels in bladder function. Acta Physiol (Oxf). 2013 Jan;207(1):110–122.
   PubMed Web of Science ®Google Scholar
• Franken J, Uvin P, De Ridder D, et al. TRP channels in lower urinary tract dysfunction. Br J Pharmacol. 2014 May;171(10):2537–2551.
   PubMed Web of Science ®Google Scholar
• Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev. 2014 Jul;66(3):676–814.
   PubMed Web of Science ®Google Scholar
• Deruyver Y, Voets T, De Ridder D, et al. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? BJU Int. 2015 May;115(5):686–697.
   PubMed Web of Science ®Google Scholar
• Merrill L, Gonzalez EJ, Girard BM, et al. Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat Rev Urol. 2016 Apr;13(4):193–204.
   PubMed Web of Science ®Google Scholar
• Moran MM. TRP channels as potential drug targets. Annu Rev Pharmacol Toxicol. 2018Jan6;58:309–330.
   PubMed Web of Science ®Google Scholar
• Moran MM, Szallasi A. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br J Pharmacol. 2018 Jun;175(12):2185–2203.
   PubMed Web of Science ®Google Scholar
• Andersson KE. TRP channels as lower urinary tract sensory targets. Med Sci (Basel). 2019 May 22;7(5):pii: E67.
   PubMedGoogle Scholar
• Apostolidis A, Brady CM, Yiangou Y, et al. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology. 2005a Feb;65(2):400–405.
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005b Sep;174(3):977–982.
   PubMed Web of Science ®Google Scholar
• de Groat WC, Yoshimura N. Changes in afferent activity after spinal cord injury. Neurourol Urodyn. 2010;29(1):63–76.
   PubMed Web of Science ®Google Scholar
• Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn. 2007 Oct;26(6 Suppl):920–927.
   PubMed Web of Science ®Google Scholar
• MacDonald R, Monga M, Fink HA, et al. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med. 2008;31:157–165.
   PubMed Web of Science ®Google Scholar
• Mourtzoukou EG, Iavazzo C, Falagas ME. Resiniferatoxin in the treatment of interstitial cystitis: a systematic review. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Nov;19(11):1571–1576.
   PubMed Web of Science ®Google Scholar
• Foster HE Jr, Lake AG. Use of vanilloids in urologic disorders. Prog Drug Res. 2014;68:307–317.
   PubMedGoogle Scholar
• Phé V, Schneider MP, Peyronnet B, et al. Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. A report from the neuro-urology promotion committee of the International Continence Society (ICS). Neurourol Urodyn. 2018 Jan;37(1):67–82.
   PubMed Web of Science ®Google Scholar
• Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):287–299.
   PubMed Web of Science ®Google Scholar
• Round P, Priestley A, Robinson J. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921–931.
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Birrell MA, Wortley MA, et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med. 2017 Nov 15;196(10):1255–1263..
   PubMed Web of Science ®Google Scholar
• Brown W, Leff RL, Griffin A, et al. Safety, pharmacokinetics, and pharmacodynamics study in healthy subjects of oral neo6860, a modality selective transient receptor potential vanilloid subtype 1 antagonist. J Pain. 2017 Jun;18(6):726–738.
   PubMed Web of Science ®Google Scholar
• Arsenault P, Chiche D, Brown W, et al. NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. Pain Rep. 2018 Oct 26;3(6):e696. eCollection 2018 Nov.
   PubMedGoogle Scholar
• Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084–19089.
   PubMed Web of Science ®Google Scholar
• Merrill L, Vizzard MA. Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats. Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R471–80.
   PubMed Web of Science ®Google Scholar
• Cheung M, Bao W, Behm DJ, et al. Discovery of GSK2193874: an orally active, potent, and selective blocker of transient receptor potential vanilloid 4. ACS Med Chem Lett. 2017 Mar 20;8(5):549–554. eCollection 2017 May 11.
   PubMed Web of Science ®Google Scholar
• Goyal N, Skrdla P, Schroyer R, et al. Clinical pharmacokinetics, safety, and tolerability of a novel, first-in-class TRPV4 ion channel inhibitor, GSK2798745, in healthy and heart failure subjects. Am J Cardiovasc Drugs. 2019 Jun;19(3):335–342.
   PubMed Web of Science ®Google Scholar
• Deruyver Y, Weyne E, Dewulf K, et al. Intravesical activation of the cation channel TRPV4 improves bladder function in a rat model for detrusor underactivity. Eur Urol. 2018 Sep;74(3):336–345.
   PubMed Web of Science ®Google Scholar
• Takaoka EI, Kurobe M, Okada H, et al. Effect of TRPV4 activation in a rat model of detrusor underactivity induced by bilateral pelvic nerve crush injury. Neurourol Urodyn. 2018 Nov;37(8):2527–2534.
   PubMed Web of Science ®Google Scholar
• Mukerji G, Yiangou Y, Corcoran SL, et al. Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urol. 2006 Mar 6;6:6.
   PubMedGoogle Scholar
• Lashinger ES, Steiginga MS, Hieble JP, et al. AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol. 2008 Sep;295(3):F803–10.
   PubMed Web of Science ®Google Scholar
• Geirsson G, Lindström S, Fall M. The bladder cooling reflex and the use of cooling as stimulus to the lower urinary tract. J Urol. 1999 Dec;162(6):1890–1896.
   PubMed Web of Science ®Google Scholar
• Uvin P, Franken J, Pinto S, et al. Essential role of transient receptor potential M8 (TRPM8) in a model of acute cold-induced urinary urgency. Eur Urol. 2015 Oct;68(4):655–661.
   PubMed Web of Science ®Google Scholar
• Ito H, Aizawa N, Sugiyama R, et al. Functional role of the transient receptor potential melastatin 8 (TRPM8) ion channel in the urinary bladder assessed by conscious cystometry and ex vivo measurements of single-unit mechanosensitive bladder afferent activities in the rat. BJU Int. 2016 Mar;117(3):484–494.
   PubMed Web of Science ®Google Scholar
• Winchester WJ, Gore K, Glatt S, et al. Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259–269.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Streng T, Waldkirch E, et al. Transient receptor potential A1 (TRPA1) activity in the human urethra–evidence for a functional role for TRPA1 in the outflow region. Eur Urol. 2009 Mar;55(3):696–704.
   PubMed Web of Science ®Google Scholar
• Weinhold P, Gratzke C, Streng T, et al. TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation. J Urol. 2010;183:2070–2076.
   PubMed Web of Science ®Google Scholar
• Du S, Araki I, Kobayashi H, et al. Differential expression profile of cold (TRPA1) and cool (TRPM8) receptors in human urogenital organs. Urology. 2008 Aug;72(2):450–455.
   PubMed Web of Science ®Google Scholar
• Streng T, Axelsson HE, Hedlund P, et al. Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol. 2008 Feb;53(2):391–399.
   PubMed Web of Science ®Google Scholar
• Andrade EL, Forner S, Bento AF, et al. TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury. Am J Physiol Renal Physiol. 2011 May;300(5):F1223–34.
   PubMed Web of Science ®Google Scholar
• Nicholas S, Yuan SY, Brookes SJ, et al. Hydrogen peroxide preferentially activates capsaicin-sensitive high threshold afferents via TRPA1 channels in the guinea pig bladder. Br J Pharmacol. 2017 Jan;174(2):126–138.
   PubMed Web of Science ®Google Scholar
• Koivisto A, Jalava N, Bratty R, et al. TRPA1 antagonists for pain relief. Pharmaceuticals (Basel). 2018 Nov 1;11(4):pii: E117.
   PubMedGoogle Scholar
• Cho CH, Lee YS, Kim E, et al. Physiological functions of the TRPM4 channels via protein interactions. BMB Rep. 2015 Jan;48(1):1–5.
   PubMed Web of Science ®Google Scholar
• Smith AC, Hristov KL, Cheng Q, et al. Novel role for the transient potential receptor melastatin 4 channel in guinea pig detrusor smooth muscle physiology. Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C467–77.
   PubMed Web of Science ®Google Scholar
• Smith AC, Parajuli SP, Hristov KL, et al. TRPM4 channel: a new player in urinary bladder smooth muscle function in rats. Am J Physiol Renal Physiol. 2013 Apr 1;304(7):F918–29.
   PubMed Web of Science ®Google Scholar
• Parajuli SP, Hristov KL, Sullivan MN, et al. Control of urinary bladder smooth muscle excitability by the TRPM4 channel modulator 9-phenanthrol. Channels (Austin). 2013 Nov-Dec;7(6):537–540.
   PubMed Web of Science ®Google Scholar
• Hristov KL, Smith AC, Parajuli SP, et al. Novel regulatory mechanism in human urinary bladder: central role of transient receptor potential melastatin 4 channels in detrusor smooth muscle function. Am J Physiol Cell Physiol. 2016 Apr 1;310(7):C600–11.
   PubMed Web of Science ®Google Scholar
• Alom F, Matsuyama H, Nagano H, et al. Involvement of transient receptor potential melastatin 4 channels in the resting membrane potential setting and cholinergic contractile responses in mouse detrusor and ileal smooth muscles. J Vet Med Sci. 2019 Feb 19;81(2):217–228.
   PubMed Web of Science ®Google Scholar
• Kullmann FA, Beckel JM, McDonnell B, et al. Involvement of TRPM4 in detrusor overactivity following spinal cord transection in mice. Naunyn Schmiedebergs Arch Pharmacol. 2018 Nov;391(11):1191–1202.
   PubMed Web of Science ®Google Scholar
• Cruz F. Transient receptor potential channel: a reality that still requires many years of scientific efforts. BJU Int. 2015 May;115(5):676–677.
   PubMed Web of Science ®Google Scholar
• Dasgupta P. Capsaicin, resiniferatoxin and botulinum toxin-A – a trip down memory lane. BJU Int. 2015 May;115(5):675.
   PubMed Web of Science ®Google Scholar
• Andersson KE. The concept of uroselectivity. Eur Urol. 1998;33(Suppl 2):7–11.
   PubMedGoogle Scholar